Silk Road Medical said today it raised $47 million in a new funding round to support its Enroute products designed for transcarotid artery revascularization procedures.
The round was led by newly invested Norwest Venture Partners and Janus Capital Management funds and joined by existing investors Warburg Pincus, The Vertical Group and CRG, the Sunnyvale, Calif.-based company said.
Silk Road’s Enroute neuroprotection system is designed to allow physicians direct access to the common carotid artery in the neck to initiate high rate temporary blood flow reversal to protect the brain from stroke during implantations of its Enroute transcarotid stent.
“TCAR represents one of the next potential multi-billion dollar medical device markets, and Silk Road is eponymous with the category with a sustainable advantage. With 13 million ischemic strokes occurring annually and carotid artery disease the culprit in up to one third of cases, the opportunity for TCAR is tremendous,” Janus Henderson Investors’ Ethan Lovell said in a prepared statement.
Read More: http://www.massdevice.com/silk-road-medical-raises-47m/
Technology is offering a new fix for one of the most confounding health-care challenges: getting patients with chronic disease to take better care of themselves.
Via: Business Wire
SAN FRANCISCO & BLOOMFIELD, Conn.--(BUSINESS WIRE)--Building on the largest enrollment quarter in the company’s history, Omada Health today announced a $50 million fundraising round led by global health services leader Cigna (NYSE: CI). In addition to leading the fundraising round, Cigna will also grow its non-exclusive commercial partnership with Omada, adding the recognized Omada Program to Cigna’s suite of health improvement services. Joining the Cigna-led fundraising round were new investors Civilization Ventures and Sanofi Genzyme BioVentures.
Via: MedCity News
Aside from Humana and Kaiser Permanente Ventures, Omada Health has scored yet another insurer investor: Cigna.
Via: KING 5
Stroke prevention is all about catching a problem before it becomes life or death. Treatment usually involves angioplasty or a stent to increase blood flow in the arteries.
Now, a new procedure promises to lower the chance of stroke during surgery by redirecting and filtering blood.
Traditional surgeries to place a stent can pose the risk of what’s called a 'procedural stroke,' that's when doctors dislodge plaque from the arteries, and it gets into the brain. But Vascular surgeons at Virginia Mason have a new tool to protect from procedural stroke called trans carotid artery revascularization or TCAR.
Here's how it works - a specialized sheath, or tube, is placed in the common carotid artery which reverses the blood flow, directing it away from the brain. That blood then runs through a filter which catches any plaque loosened during the procedure. Finally, a stent is placed in the artery through the same sheath used to reverse blood flow.
Read More: www.king5.com/news/local/new-procedure-help-prevent-procedural-stroke-at-virginia-mason/447989054
Oxygen-rich blood generally flows from the heart to the brain, but a new technology aimed at preventing strokes temporarily reverses that path.
Outset Medical Sets Out To Upend Dialysis
BEND, Ore. - St. Charles Bend announced Monday it is the first hospital in Oregon to offer a new treatment program for patients at risk for stroke due to blockages in their neck arteries.
Q1 Cash Balance of $156.9M — Cash Through Q3 2019
Phase 1a Study Will Assess Novel Checkpoint Inhibitor as a Single Agent in Solid Tumors